Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Interest & Investment Income (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Interest & Investment Income for 5 consecutive years, with $58.1 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income rose 96.3% to $58.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $70.5 million through Dec 2025, up 1.24% year-over-year, with the annual reading at $70.5 million for FY2025, 1.24% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $58.1 million at BeOne Medicines, up from $3.0 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $58.1 million in Q4 2025, with the low at $3.0 million in Q3 2025.
  • Average Interest & Investment Income over 3 years is $18.7 million, with a median of $14.7 million recorded in 2024.
  • Peak annual rise in Interest & Investment Income hit 96.3% in 2025, while the deepest fall reached 73.56% in 2025.
  • Over 3 years, Interest & Investment Income stood at $20.6 million in 2023, then skyrocketed by 43.49% to $29.6 million in 2024, then skyrocketed by 96.3% to $58.1 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $58.1 million, $3.0 million, and $3.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.